Blood pressure reduction in secondary stroke prevention

CONTINUUM Lifelong Learning in Neurology

Volumn 17, Issue 6, 2011, Pages 1233-1241

  Qureshi, Adnan I ^a   Sapkota, Biggya L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; INDAPAMIDE; LABETALOL; NIMODIPINE; NITRENDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN;

ADULT; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CASE REPORT; CHRONIC DISEASE; COMORBIDITY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; HEART INFARCTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MALE; PREVALENCE; RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SINUS TACHYCARDIA; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; STROKE PATIENT; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

EID: 84856101586     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000410032.34477.58     Document Type: Review

References (24)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association. Heart disease and stroke statisticsV2010 update: a report from the American Heart Association. Circulation 2010; 121(7): e46-e215.
2. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010; 376(9735): 112-123.
3. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statisticsY2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115(5): e69-e171. (Pubitemid 46226160)
4. Qureshi AI, Suri MF, Kirmani JF, Divani AA. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000 Med Sci Monit 2005; 11(9): CR403-CR409. (Pubitemid 41330130)
5. Pullicino PM, McClure LA, Wadley VG, et al. Blood pressure and stroke in heart failure in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Stroke 2009; 40(12): 3706-3710.
6. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289(19): 2534-2544. (Pubitemid 37430155)
7. Blood Pressure Lowering Treatment Trialists' Collaboration; Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336(7653): 1121-1123. (Pubitemid 351731743)
8. Chrysant SG, Chrysant GS. Effectiveness of lowering blood pressure to prevent stroke versus to prevent coronary events. Am J Cardiol 2010; 106(6): 825-829.
9. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54(12): 1044-1054.
10. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl) 1995; 108(9): 710-717.
11. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145-153. (Pubitemid 30051645)
12. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack [published errata appears in Lancet 2001; 358(9292): 1556; Lancet 2002; 359(9323): 2120]. Lancet 2001; 358(9287): 1033-1041.
13. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003; 34(11): 2741-2748. (Pubitemid 37392777)
14. Schrader J, Lü ders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36(6): 1218-1226.
15. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359(12): 1225-1237.
16. Diener HC. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs. J Hypertens Suppl 2009; 27(5): S31-S36.
17. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42(1): 227-276.
18. Bath P, Chalmers J, Powers W, et al; International Society of Hypertension Writing Group. International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. J Hypertens 2003; 21(4): 665-672. (Pubitemid 36549655)
19. Wahlgren NG, MacMahon DG, De Keyser JD, et al. Intravenous Nimodipine West European Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis 1994; 4(3): 204-210.
20. Sieg-Dobrescu D, Burnier M, Hayoz D, et al. The return of increased blood pressure after discontinuation of antihypertensive treatment is associated with an impaired post-ischemic skin blood flow response. J Hypertens 2001; 19(8): 1387-1392. (Pubitemid 32730455)
21. Robinson TG, Potter JF, Ford GA, et al; COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol 2010; 9(8): 767-775.
22. Ovbiagele B, Hills NK, Saver JL, Johnston SC. Antihypertensive medications prescribed at discharge after an acute ischemic cerebrovascular event. Stroke 2005; 36(9): 1944-1947. (Pubitemid 41266532)
23. Schrader J, Lü ders S, Kulschewski A, et al; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34(7): 1699-1703. (Pubitemid 36842630)
24. Sandset EC, Bath PM, Boysen G, et al; SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomized, placebo-controlled, double-blind trial. Lancet 2011; 377(9767): 741-750.